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Neuropilin 1 (NRP1) is expressed by neurons, blood vessels, immune cells and many other cell types in
the mammalian body and binds a range of structurally and functionally diverse extracellular ligands to
modulate organ development and function. In recent years, several types of mouse knockout models
have been developed that have provided useful tools for experimental investigation of NRP1 function,
and a multitude of therapeutics targeting NRP1 have been designed, mostly with the view to explore
them for cancer treatment. This review provides a general overview of current knowledge of the sig-
nalling pathways that are modulated by NRP1, with particular focus on neuronal and vascular roles in the
brain and retina. This review will also discuss the potential of NRP1 inhibitors for the treatment for
neovascular eye diseases.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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neurons and blood vessels, and constitutive NRP1 knockout mice
are embryonically lethal with both neural and vascular defects
(Kawasaki et al., 1999; Kitsukawa et al., 1997; Lampropoulou and
Ruhrberg, 2014; Schwarz and Ruhrberg, 2010). Since its discovery
in 1987 as a cell adhesion molecule termed A5 in the frog nervous
system (Takagi et al., 1987), an excess of 1775 PubMed citations
have become available that have either examined the structure,
expression or function of NRP1 in organ development or pathology.
These studies have deﬁned NRP1 roles in a range of signalling
pathways that utilise diverse extracellular ligands. In particular,
NRP1's ability to modulate vascular responses in tumour growth
has sparkedmuch interest inmanipulating its function. Some of the
emerging therapeutics to modulate NRP1 function have provided
useful tools for experimental investigation and have clinical po-
tential to treat ocular neovascular diseases such as retinopathy of
prematurity (ROP), proliferative diabetic retinopathy (PDR) and
age-related macular degeneration (AMD) (Foster and Resnikoff,
2005). This review provides a general overview of current knowl-
edge of signalling pathways that are modulated by NRP1 and will
discuss clinical potential of NRP1 targeting to treat neovascular eye
disease.1. Structure of the neuropilins (NRPs)
Both NRP1 and its homolog NRP2 are glycoproteins encoded by
genes that are alternatively spliced into full-length transmembrane
receptors and shorter soluble forms (Gagnon et al., 2000) (Fig. 1).
The NRP1 transmembrane form is encoded by 17 exons and
composed of an extracellular domain of about 840 amino acids, a
single-pass transmembrane domain of 23 amino acids and a 44
amino acid cytoplasmic domain (Schwarz and Ruhrberg, 2010). The
importance of NRP1 for a host of diverse developmental and
pathological processes can be explained by its organisation into
several structurally distinct domains (Fig. 1A) that mediate in-
teractions with many different other proteins and are alternatively
spliced. The extracellular NRP1 part consists of two domains called
a1 and a2, which resemble the CUB (complement, Uegf, BMP)
domain present in complement components. They are followed by
the b1 and b2 domains, which are similar to coagulation factor V/
VIII domains. The c domain, with homology to a MAM (meprin/antigen 5/receptor tyrosine phosphatase m domain), separates the
other extracellular domains from the transmembrane region. The
short intracellular (cytoplasmic) domain is catalytically inactive,
but contains a C-terminal SEA (serine-glutamine-alanine) motif
that interacts with intracellular proteins containing a PDZ domain
(Schwarz and Ruhrberg, 2010).
NRP2 was identiﬁed based on its homology to NRP1 (Chen et al.,
1997). The amino acid sequences of the corresponding a, b and c
domains of human NRP1 and NRP2 are 45%, 48%, and 35% identical
(Fig. 1B). Two NRP2 alternative splicing variants exist, NRP2A and
NRP2B (Gu et al., 2003; Nakamura et al., 2000; Schwarz and
Ruhrberg, 2010) (Fig. 1B). Human NRP2A and NRP2B have iden-
tical a, b, and c domains, but their sequence differs after amino acid
808, which localises in the linker region connecting the c domain
and transmembrane domains. The NRP2A cytoplasmic domain
shares 53% identity with the NRP1 cytoplasmic domain and also has
a SEA motif, whereas the NRP2B cytoplasmic domain lacks the SEA
motif and is unable to interact with PDZ domain containing pro-
teins (Rossignol et al., 2000).
Soluble forms of both NRP1 and NRP2 have also been described
(Fig. 1A). The soluble forms s11NRP1 and s12NRP1 are encoded by
the ﬁrst 11 and 12 exons of the NRP1 gene, respectively, and s9NRP2
is encoded by the ﬁrst 9 exons of the NRP2 gene (Gagnon et al.,
2000; Rossignol et al., 2000). More recently, transcripts for two
additional soluble isoforms, named sIIINRP1 and sIVNRP1, were
identiﬁed in a human expression sequence tag (EST) clone library
(Cackowski et al., 2004). sIIINRP1 contains the sequence encoded by
the ﬁrst 9 exons and exon 12, but skips exons 10 and 11, whereas the
sIVNRP1 mRNA contains the ﬁrst 10 exons and exon 12, but lacks
exon 11. As all soluble NRP1 isoforms lack the c, transmembrane
and cytoplasmic domains (Fig. 1A), they can bind NRP1 ligands, but
are unable to transduce signals and thus may serve as decoy re-
ceptors to sequester NRP1 ligands (Gagnon et al., 2000). Whilst
soluble NRP1 is expressed in cells of the liver and kidney (Gagnon
et al., 2000), little is known about its endogenous functions. In
contrast, transmembrane NRP1, but not soluble NRP1 is expressed
in blood vessels (Gagnon et al., 2000). Transmembrane NRP1 has
been implicated in the development and function of numerous
tissues, most notably blood vessels and neurons. The multiple
neurovascular functions of the transmembrane isoform of NRP1 are
therefore the main topic of this review.
Fig. 1. Structure of NRP1, NRP2 and their splice variants. (A) Schematic representation of the transmembrane and soluble forms of both NRPs. Transmembrane NRP forms consist of
seven domains, two complement (CUB) domains (a1 and a2), two coagulation factor (FV/FVIII) domains (b1 and b2), a MAM domain (c), a transmembrane region (TM) and a
cytoplasmic (cyto) domain that interacts with intracellular proteins containing a PDZ domain. Soluble NRPs have the a and b domains, but lack the transmembrane and cytoplasmic
domains. (B) Amino acid identity between corresponding domains in transmembrane NRP1 and the NRP2 splice variants NRP2a and NRP2b; the grey line indicates the position after
which NRP2A and NRP2B have no more homology.
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diverse ligands
Even though NRP1 was originally identiﬁed as an adhesion
molecule in the nervous system (Takagi et al., 1995), it has since
been studied primarily as a receptor for the class 3 semaphorin
(SEMA3) A, a secreted glycoprotein that regulates axon guidance
(He and Tessier-Lavigne, 1997; Kolodkin and Ginty, 1997), and as a
receptor for speciﬁc isoforms of the vascular endothelial growth
factor A (VEGF) (e.g. Soker et al., 1996, 1998). Similarly, NRP2 has
been described both as a SEMA3 family and VEGF isoform receptor
(e.g. Chen et al., 1997; Giger et al., 1998; Gluzman-Poltorak et al.,
2000).
The SEMA3 class of secreted semaphorins is comprised of
SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, SEMA3F and
SEMA3G (reviewed in Neufeld et al., 2012). Whereas NRP1 pre-
dominantly binds SEMA3A as well as SEMA3C, NRP2 preferentially
binds SEMA3F and SEMA3C, but also SEMA3B, SEMA3D and
SEMA3G (reviewed in Raper, 2000; Sharma et al., 2012). Even
though NRP1 acts mainly as a SEMA3A receptor and NRP2 as a
SEMA3F receptor, there are exceptions to this general rule (see
Section 5).
The VEGFA gene consists of 8 exons and encodes three major
alternatively spliced isoforms termed VEGF189, VEGF165 and
VEGF121 in humans and VEGF188, VEGF164 and VEGF120 in mice,
respectively, with the numbers indicating the number of amino
acids in the mature polypeptide (reviewed in Ruhrberg, 2003).
These isoforms differ by the presence or absence of protein do-
mains expressed by exon 6 and 7, with VEGF189 containing both
domains and VEGF165 containing the domain encoded by exon 7and VEGF121 lacking both the exon 6 and 7 domains. Exons 6 and 7
as well as the shared C-terminal exon 8 have all been implicated in
VEGF isoform binding to NRPs. As described in the following par-
agraphs, structure-function studies of NRP1 have shown that
binding to these diverse ligands is mediated by the a and b
domains.
The a1 and a2 domains confer SEMA3 binding speciﬁcity, and
NRP1 mutant proteins lacking the a1 or a2 domains fail to bind
SEMA3A in vitro (Gu et al., 2002). In contrast, these SEMA3A
binding-deﬁcient mutants retain the ability to bind VEGF165 (Gu
et al., 2002). Point mutations have been introduced into the a1
domain to create a mouse mutant that lacks SEMA3A-, but not
VEGF165-binding to NRP1 (Gu et al., 2003). Analysis of these mice
has provided much insight into NRP1 function in the vascular and
nervous systems (see Sections 3, 4 and 5). The b1 domain addi-
tionally contributes to the binding of SEMA3 proteins that have
been proteolytically cleaved by furin endopeptidases to expose a C-
terminal arginine that binds the b1-b2 domain (Gu et al., 2002;
Parker et al., 2010, 2012a).
VEGF165 binds to NRP1 via the b1 and b2 domains (Gu et al.,
2002; Mamluk et al., 2002). Whereas loss of the b1 domain abro-
gates VEGF165 binding to NRP1, loss of the b2 domain only reduces
NRP1 afﬁnity for VEGF165 (Gu et al., 2002). Recent evidence
showed that NRP1 b1 domain mutants with point mutations
replacing tyrosine residue 297 with alanine (Y297A) or aspartate
residue 320 with lysine or alanine (D320K or D320A) are unable to
bind VEGF165, but maintain SEMA3A binding (Gelfand et al., 2014;
Herzog et al., 2011).
Although VEGF165 is themain VEGF-A isoform that binds NRP1
(Soker et al., 1998), VEGF121 and VEGF189 are also capable of
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ated by the exon 8-encoded domain, which carries a C-terminal
arginine residue (Pan et al., 2007b; Parker et al., 2012b). However,
the afﬁnity of VEGF121 for NRP1 is 10 times lower than that of
VEGF165 (Parker et al., 2012b). In agreement, in situ ligand-
binding assays with alkaline phosphatase-conjugated VEGF iso-
forms on intact mouse brain tissue demonstrated that VEGF165
binds NRP1-expressing axon tracts in vivo, but that VEGF121 is
unable to do so (Tillo et al., 2015; Vieira et al., 2007). Similar
studies also showed that VEGF189 binds NRP1 (Tillo et al., 2015).
Biochemical studies demonstrated that NRP1 VEGF189 has higher
afﬁnity than VEGF165 for NRP1, mainly due to a lower dissociation
constant that may be explained by VEGF189 containing both the
exon 6- and 7, as well as the exon 8-encoded domains (Vintonenko
et al., 2011).
Recently, VEGF165b was identiﬁed as another alternative splice
form of VEGF. VEGF165b is identical to VEGF165, except for the last
six amino acids, which are encoded by an alternative exon 8, and it
therefore has a different C-terminal domain (Bates et al., 2002).
Although VEGF165b contains the exon 7-encoded domain, it does
not interact with NRPs, demonstrating that the C-terminus enco-
ded by exon 8 of the other VEGF isoforms is critical for its the
interaction with NRPs (Vander Kooi et al., 2007).
Similar to NRP1, NRP2 binds VEGF165, and additionally, a less
common VEGF isoform termed VEGF144 (Gluzman-Poltorak et al.,
2000). However, NRP2 has a 50 fold lower afﬁnity for VEGF165
compared to NRP1, likely due to the different amino acid sequence
in the b1 domain (Parker et al., 2012b).
The NRP1 b1 and b2 domains additionally serve as binding
sites for several other ligands, in particular those that share
homology with VEGF, including VEGFB, VEGFC, VEGFD and the
placental growth factor 2 PLGF2 (also known as PGF) (Karpanen
et al., 2006; Makinen et al., 1999; Migdal et al., 1998). NRP1 also
binds hepatocyte growth factor (HGF), several members of the
ﬁbroblast growth factor (FGF) family as well as latent and active
transforming growth factor beta 1 (TGFb1) (Glinka and
Prud'homme, 2008; Hu et al., 2007; West et al., 2005). The
ability of the NRP1 b1 domain to bind these proteins may be
linked to its ability to function as a heparin mimetic that sup-
ports ionic bonding with the heparin-binding site of growth
factors (West et al., 2005).
The b1 and b2 domains are also required for NRP1-mediated cell
adhesion activity (Shimizu et al., 2000). The cell adhesion ligand for
NRP1 is an unidentiﬁed protein distinct from SEMA3A or VEGF
(Shimizu et al., 2000).
1.2. The cytoplasmic NRP1 domain recruits intracellular proteins
The 44 amino acid NRP1 cytoplasmic domain has no known
catalytic activity, but contains a SEA motif that is able to recruit the
PDZ domain-containing adaptor protein synectin (Gao et al., 2000),
also known as GIPC1 (Cai and Reed,1999). Synectin bindsmyosin VI
to enable NRP1 trafﬁcking into early endosomes (Lanahan et al.,
2010). The NRP1 cytoplasmic domain has also been reported to
interact with the non-receptor tyrosine kinase ABL1 in tumour cells
(Yaqoob et al., 2012). The role of these NRP1 cytoplasmic domain
interactions is discussed in detail below (Section 4.4.1 and Section
5.1). According to the phosphosite bioinformatics resource (www.
phosphosite.org), an excess of 485 high throughput proteomic
discovery-mode mass spectrometry analyses identiﬁed post-
translational phosphorylation of human NRP1 at Y920, which is
located next to the SEA domain. Post-translational modiﬁcation of
the NRP1 cytoplasmic tail may enable modulation of NRP1 signal-
ling, but their existence has yet to be validated through conven-
tional biochemical analyses.1.3. NRPs form complexes with several receptors and intracellular
adaptors
The c domain of NRP1 mediates homodimerisation and heter-
odimerisation with NRP2 (Gluzman-Poltorak et al., 2001; Herzog
et al., 2011). Experiments in which the NRP1 transmembrane and
cytoplasmic domains are absent or replaced by the corresponding
NRP2 sequences suggest that the transmembrane domain and
intracellular domain of NRP1 are not sufﬁcient for dimerisation
(Nakamura et al., 1998). In fact, it is the c and transmembrane do-
mains that mediate dimer formation (Giger et al., 1998; Roth et al.,
2008).
NRP1 and NRP2 interact with transmembrane proteins of the
plexin (PLXN) family to convey semaphorin signals, with NRPs
serving as the ligand binding and plexins serving as signal trans-
ducing subunits (reviewed in Schwarz and Ruhrberg, 2010). The
cytoplasmic domain of plexins contains a GTPase-activating protein
(GAP) domain that stimulates signal transduction, but a
semaphorin-binding domain in the extracellular PLXN domain
maintains PLXN in an inactive conformation unless the SEMA3/NRP
complex is bound to the PLXN (Takahashi and Strittmatter, 2001).
NRP1 can also form VEGF165-dependent complexes with the
VEGF receptor tyrosine kinase 2 (VEGFR2, also known as KDR or
FLK1) (e.g. Soker et al., 2002). VEGF165 contains a cysteine knot
motif encoded by exon 4 that contacts VEGFR2 in addition to its
exon 7/8-encoded region that interacts with NRP1 to enable bridge
formation between both receptors; hence, mutations of either Y297
or D320 in NRP1 exon 6, which impair VEGF165 binding, inhibit
complex formation between NRP1 and VEGFR2 (Herzog et al.,
2011). Even though VEGF121 has the exon 4-encoded domain and
binds NRP1 via its exon 8-encoded domain, this interaction is not
sufﬁcient to enable complex formation between NRP1 and VEGFR2,
at least in vitro (Pan et al., 2007b).
Similar to NRP1, NRP2 has been shown to interact with VEGFR2
in a VEGF165-dependent manner in vitro (Favier et al., 2006). Both
NRP1 and NRP2 can also form a complex with VEGFR1 in cells
overexpressing these proteins, and complex formation is stimu-
lated by both VEGF165 and VEGF121 (Fuh et al., 2000; Gluzman-
Poltorak et al., 2001). Additionally, NRP2 interacts with VEGFR2
and VEGFR3 in a VEGFC-dependent manner (Favier et al., 2006).
NRP1 has been observed to interact with integrins, receptors for
extracellular matrix components such as ﬁbronectin, laminin and
collagen. Two integrins have been identiﬁed in endothelial cells,
the ﬁbronectin receptor a5b1 integrin and the vitronectin receptor
avb3 (e.g (Dejana et al., 1990). In vitro studies showed that NRP1
interacts with the b1 subunit in human cancer and arterial endo-
thelial cells (Fukasawa et al., 2007; Serini et al., 2003). Most
recently, co-immunoprecipitation analysis of brain lysates revealed
that NRP1 forms a complex with b8 integrin on neuroepithelial
cells (Hirota et al., 2015). The functional signiﬁcance of NRP1 in-
teractions will be discussed in Section 4.1.
Similar to NRP1, NRP2 interacts with integrins in different cell
types. Thus, immunoprecipitation analysis revealed that NRP2 in-
teracts with a5 integrin in endothelial cells (Cao et al., 2013) and
with a6b1 integrin in melanoma and breast cancer cells (Goel et al.,
2012).
Both NRP1 and NRP2 form a complex with the TGFb receptor 1
(TGFBR1) and the TGFb receptor 2 (TGFBR2), independently of
TGFb1 binding (Glinka et al., 2011). Biochemical studies showed
that NRP1 and NRP2 have a similar afﬁnity for TGFBR1, whereas
NRP2 has a higher afﬁnity for TGFBR2 compared to NRP1 (Glinka
et al., 2011). NRPs role in TGFb signalling will be further discussed
in Section 4.2.
In human mesenchymal stem cells, NRP1 also interacts with
PDGFRa in the presence of PDGFA, PDGFB or VEGF165, and with
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therefore appears likely that these ligands enable bridge formation,
akin to the role of VEGF165 in NRP1-VEGFR2 complex formation.
NRP1 also forms a complex with PDGFRa in primary human aortic
smooth muscle cells (Evans et al., 2011; Pellet-Many et al., 2011).
NRPs role in PDGFR signalling will be further discussed in Section
4.3.
2. Models to study the functional signiﬁcance of SEMA3 and
VEGF signalling through NRP1
The functional signiﬁcance of SEMA3 and VEGF signalling
through NRP1 has been studied in several different contexts,
including in neuronal and vascular development, tumourigenesis,
ocular neovascular disease and immune system function
(Chaudhary et al., 2014; Ellis, 2006; Fantin et al., 2012; Graziani and
Lacal, 2015; Plein et al., 2014). This review will largely focus on
current literature describing NRP1's neurovascular roles in devel-
opment and disease, with speciﬁc reference to the brain and retina.
2.1. The mouse hindbrain and retina as models to study
neurovascular development
Themouse embryo hindbrain and retina arewidely usedmodels
for the qualitative and quantitative description of molecular and
cellular mechanisms regulating neovascularisation. The hindbrain
is vascularised early in development to support the growth of
rapidly proliferating neural progenitors and the function of their
progeny, and vascularisation follows a stereotypical process
(reviewed by Ruhrberg and Bautch, 2013). Thus, vessels sprout
from the perineural vascular plexus into the mouse hindbrain at
around embryonic day (E) 9.75 towards the ventricular zone, and
the ﬁrst intraneural vascular network beneath the hindbrain ven-
tricular zone is established by E12.5 (Fantin et al., 2010; Ruhrberg
et al., 2002). Hindbrain vascularisation is described in more de-
tails in Section 5.
The retinal vasculature is comprised of three layers, a superﬁcial,
deep and intermediate plexus (reviewed by Fruttiger, 2002;
Ruhrberg and Bautch, 2013). The superﬁcial vascular plexus forms
when vessels originating in the optic nerve invade the retina and
grow centrifugally towards the retinal periphery during the ﬁrst
week after birth in rodents. From postnatal (P) day 7 onwards, the
superﬁcial vascular plexus sprouts vertically to form ﬁrst the deep
and then the intermediate vascular plexus (Fruttiger, 2002;
Ruhrberg and Bautch, 2013). By P12, the deep plexus has reached
the retinal periphery. This is followed by growth of the interme-
diate plexus in the inner plexiform layer, and by p21 the retinal
vasculature is mature and efﬁciently perfuses the retina (reviewed
in Fruttiger, 2002; Ruhrberg and Bautch, 2013; Stahl et al., 2010).
The hindbrain model is particularly useful to analyse angio-
genesis in mouse mutants suffering midgestation lethality. In
contrast, retinal angiogenesis in rodents occurs postnatally and is
therefore not suitable to study embryonically lethal mouse mu-
tants. However, both models can be adapted to study angiogenesis
in inducible endothelial-speciﬁc conditional knockout mice to
overcome embryonic lethality (Fantin et al., 2013b; Plein et al.,
2015b). Both the hindbrain and retina models have been used
extensively to deﬁne the function of NRP1 and its ligands in
developmental angiogenesis (see Section 5).
2.2. Neovascular eye diseases and relevant mouse models
Ocular neovascularisation causes visual loss in several diseases
including ROP, PDR, BRVO and exudative AMD (reviewed in
Campochiaro, 2013, 2015). The role of disregulated VEGF or SEMAsignalling through NRP1 in these conditions will be discussed in
subsequent chapters following a brief overview of these conditions
and relevant mouse models.
ROP occurs in premature neonates that receive oxygen therapy
during intensive care because of their immature lungs. Increased
oxygen levels destabilise the immature developing vasculature of
the retina, and the ensuing vascular regression causes hypoxia on
return to room air. Hypoxia then stimulates the growth of neo-
vessels that are fragile, leaky and protrude into the vitreous,
causing haemorrhage, retinal scarring and retinal detachment
(Campochiaro, 2015). In PDR, a leading cause of blindness in adults
of working age, diabetic metabolic syndrome causes retinal capil-
lary degeneration and occlusions which result in retina ischemia.
The ischemic tissues increase the synthesis of pro-angiogenic fac-
tors, which stimulate the growth of abnormal leaky vessels from
pre-existing retinal venules, promoting the development of dia-
betic macular oedema (DME). The mouse oxygen-induced reti-
nopathy (OIR) model has many hallmarks of human ROP and PDR
(Smith et al., 1994). In the OIRmodel, the exposure of neonatal mice
to hyperoxia induces vaso-obliteration of central retinal capillaries,
which on subsequent return of mice to normoxia causes tissue
hypoxia and neovascularisation. Whilst there is some revascular-
isation of avascular areas, neovascular pathology is characterised by
tuft-like vascular malformations from veins and capillaries that
have escaped regression (Connor et al., 2009; Smith et al., 1994).
These vascular malformations protrude into the vitreous instead of
re-establishing a functional vascular network in the ischemic areas
of the retina. The OIR model has been used recently to deﬁne the
function of NRP1 and its ligands in retinal neovascularisation,
whilst a mouse model of diabetes has also been used to study the
role of NRP1 and its ligands in diabetic retinopathy and ocular
oedema (Section 6).
Retinal vein occlusions (RVO) are the secondmost common type
of retinal vascular disorder after diabetic retinal disease, can occur
at almost any age, but mostly in patients aged over 50, and they
cause sudden unilateral loss of vision (Rogers et al., 2010). While
central RVO (CRVO) results from thrombosis in the central retinal
vein within the optic nerve, branch RVO (BRVO) occurs at more
distal sites due to focal occlusion of a retinal vein at an arterio-
venous crossing-point, where compression of the vein by an ar-
tery passing anteriorly produces turbulence and thrombosis (Cahill
and Fekrat, 2002). Loss of vision in these conditions is usually
secondary to neovascularisation and retinal oedema (Campochiaro,
2015). A mouse model of BRVO has recently been developed, which
involves laser-induced photocoagulation of a retinal vein after
systemic injection of rose bengal (Zhang et al., 2007). Several
different genetically engineered mouse mutants have been re-
ported to increase the frequency of arteriovenous crossings in the
retina, including some affecting NRP1 (see section 4.4.1). As arte-
riovenous crossings in the retina are a known risk factor for BRVO
(Weinberg et al., 1990; Zhao et al., 1993), these mouse models may
be useful to study the pathogenesis of BRVO.
AMD is the leading cause of severe visual loss in people over the
age of 65. In contrast to ROP and PDR, in which retinal neo-
vasculature invades the vitreous cavity, neovascularisation in AMD
originates from the choroidal vasculature and extends into the
subretinal space of the macula, the area of retina responsible for
central vision, thus causing loss of vision (reviewed in
Campochiaro, 2015). Amodel of choroidal neovascularisation (CNV)
induced by laser injury of the Bruch's membrane that separates the
choroidal vasculature from the retinal pigment epithelium (RPE)
and the neural retina exist in the mouse. In this model, the laser
injury ruptures the outer blood-retina barrier, causes inﬂammation
and induces CNV towards the neural retina and vascular leakage
(Balaggan et al., 2006). Even though a recent report linked genetic
C. Raimondi et al. / Progress in Retinal and Eye Research 52 (2016) 64e83 69variation in NRP1 to treatment response in patients with neo-
vascular AMD (see Section 6), NRP1 function has not yet been
studied in the CNV model.
3. Functional signiﬁcance of SEMA3 signalling though NRPs
SEMA3 signalling through NRPs has been shown to regulate a
multitude of cell behaviours, in particular in the central and pe-
ripheral nervous system, but also in the cardiovascular and immune
systems. Cell type- and context-speciﬁc cellular responses are
achieved, in part, through the association of the NRPs with different
plexins and the contribution of speciﬁc intracellular signal trans-
duction pathways (reviewed in Schwarz and Ruhrberg, (2010).
3.1. SEMA3 signalling through NRPs in neurons
Several SEMA3 proteins signal through NRPs to regulate
neuronal migration, axon guidance or dendrite development
(reviewed in Schwarz and Ruhrberg, 2010; Tillo et al., 2012). For
example, SEMA3A knockout mouse mutants have defasciculation
of cranial and spinal nerves (Taniguchi et al., 1997) and defective
path ﬁnding of olfactory axons (Cariboni et al., 2011; Schwarting
et al., 2000). Agreeing with a role for NRP1 as a SEMA3A receptor
in the nervous system, NRP1-null mice phenocopy many neural
defects seen in SEMA3A-null mice (e.g. Kawasaki et al., 2002).
Whilst most neural SEMA3A responses involve repulsion, increased
intracellular cyclic GMP levels can convert repulsive effects into
attractive ones, as observed for cortical apical dendrites (Polleux et
al., 2000). Even though NRP1 acts mainly as a SEMA3A receptor,
and NRP2 as a SEMA3F receptor in neurons, NRP2 can compensate
for NRP1 as a SEMA3A-receptor during glioma cell migration
in vitro and in vomeronasal axon guidance in mouse embryos
in vivo (Cariboni et al., 2011).
Whilst SEMA3A is generally thought to be downregulated after
development is complete, its expression increases locally after
injury in mouse models of peripheral nerve injury, where it repels
regenerating axons and thereby inhibits the rewiring of the
damaged area (Pasterkamp and Verhaagen, 2001). Moreover,
inhibiting SEMA3A-dependent signalling with an allosteric
competitor of SEMA3A for NRP1 binding in the injured spinal cord
creates a more permissive environment for axonal regeneration
in vivo by promoting angiogenesis, Schwann cell migration and the
Schwann cell-mediated myelination of regenerating neuronal ﬁ-
bers (Kaneko et al., 2006).
In the developing Xenopus eye, SEMA3A is expressed in the lens
and photoreceptors, SEMA3D in the proliferative ciliary marginal
zone of the peripheral retina and SEMA3F in neuronal cells of the
inner nuclear layer, whilst NRP1 localises to retinal ganglion cell
(RGC) axons and dendrites (Kita et al., 2013). Expressing dominant-
negative NRP1 or PLXNA1 mutants causes dendrites to extend in
various directions from the RGC cell body and therefore prevents
the polarised extension of dendrites towards the inner nuclear
layer, in the opposite direction of axon extension (Kita et al., 2013).
SEMA3A is also upregulated during optic nerve injury, and down-
regulating its expression may provide a therapeutic strategy to
treat this condition, as decreasing SEMA3A expression promotes
axon outgrowth in RGCs and reduces apoptosis (Han et al., 2015a;
Rosenzweig et al., 2010; Shirvan et al., 2002). The pathological
upregulation of SEMA3A in RGCs is also observed in ischemic eye
disease, where it promotes the formation of vascular malforma-
tions (see below, Sections 3.3, 6.2 and 6.3).
3.2. SEMA3A signalling through NRPs in the vasculature
SEMA3A, SEMA3C and SEMA3E have been implicated asmodulators of the developing vasculature. SEMA3E affects blood
vessels independently of NRPs by signalling through PLXND1 (Gu
et al., 2005) and will therefore not be a focus of this review.
SEMA3C signals through NRP1/PLXND1 complexes during cardiac
outﬂow tract remodelling (Plein et al., 2015a), but this also will not
be discussed further. SEMA3A was originally thought to modulate
vascular development in the embryo (Serini et al., 2003), but sub-
sequent analyses showed that SEMA3A knockout mice lack obvious
defects in developmental blood vessel growth (Bouvree et al., 2012;
Vieira et al., 2007). In agreement, loss of semaphorin binding to
NRP1 does not affect angiogenesis in mouse embryos, even if they
additionally lack NRP2 (Gu et al., 2005; Vieira et al., 2007). Yet,
SEMA3A signals through NRP1 to control the development of
lymphatic valves (Bouvree et al., 2012; Ochsenbein et al., 2014).
Moreover, the in utero delivery of antibodies that inhibit SEMA3A
binding to NRP1 causes abnormal lymphatic vessel and valve
morphology (Jurisic et al., 2012). The main role for SEMA3A in the
vasculature, however, appears to be the modulation of vascular
pathology: Firstly, SEMA3A signals through NRP1 to promote
pathological angiogenesis in the eye (Joyal et al., 2011) (see Section
2.2.1). Secondly, SEMA3A signals through NRP1 or NRP2 to induce
vascular hyperpermeability in the eye and other tissues (Acevedo
et al., 2008; Cerani et al., 2013; Hou et al., 2015) (see Sections 6.2
and 6.3).
3.3. SEMA3A in rodent models of neovascular eye pathology
RGCs express SEMA3A during the hyperoxic phase in the OIR
model, and this SEMA3A source repels sprouting vessels away from
the most severely ischemic areas after return to normoxia, thus
misdirecting them into the vitreous and causing tuft formation
(Joyal et al., 2011). The release of interleukin 1 beta from microglia,
the resident myeloid population of the retina is responsible for the
induction of SEMA3A expression by RGCs (Rivera et al., 2013).
Agreeing with an important role for SEMA3A in neovascular tuft
formation, administering exogenous SEMA3A into the vitreous re-
duces pathological neovascularisation in the OIR model (Yu et al.,
2013). SEMA3A has also been shown to inhibit VEGF164-induced
angiogenesis in the chick chorioallantoic model of pathological
vessel growth (Acevedo et al., 2008), raising the possibility that the
effect of SEMA3A on blocking neovascular tuft formation is two-
fold, ﬁrstly by redirecting neovessels away from the vitreous, and
secondly by inhibiting VEGF-induced neovessel growth. Treatment
with SEMA3A was also reported to block the formation of neo-
vascular lesions after laser-induced CNV by inhibiting TGFb sig-
nalling in endothelial cells (Bai et al., 2014) (see Sections 5.2 and
6.2.1).
3.4. SEMA3A signalling through NRPs in vascular permeability
A diverse range of secreted proteins can induce vascular
hyperpermeability, which is also referred to as acute vascular
permeability (Weis and Cheresh, 2005). Whilst it is a beneﬁcial
process in acute injury to deliver clotting factors and antibodies to
enable wound healing, vascular hyperpermeability can cause
tissue-damaging oedema when it remains unresolved, and it is
therefore an unwanted complication in many chronic neovascular
diseases, especially in the eye (reviewed by Campochiaro, 2015;
Weis and Cheresh, 2005). NRP1 has been implicated as a perme-
ability mediator in several studies. Initially, it was shown that
SEMA3A injection into adult mouse skin induces vascular hyper-
permeability in a NRP1-dependent mechanism (Acevedo et al.,
2008; Hou et al., 2015). Whereas SEMA3A is not highly expressed
in the healthy retina of adult mice, SEMA3A expression is upregu-
lated in a mouse model of type 1 diabetes induced by
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et al., 2013). As observed in the skin, SEMA3A-induced retinal
vascular leak in diabetic mice was NRP1-dependent (Cerani et al.,
2013). SEMA3A is also upregulated during the early hyper-
glycaemic phase of diabetes in humans, raising the possibility that
it presents a therapeutic target to stem excessive vascular perme-
ability in DME (Cerani et al., 2013). SEMA3A also induces brain
endothelial vascular leak when injected stereotactically into the
cerebral cortex and in models of brain ischemia (Hou et al., 2015).
However, using cultured brain endothelial cells, this study found
SEMA3A to act via NRP2 and VEGFR1, independently of NRP1,
whereby VEGFR1 interacts with the actin regulator MICAL2 to alter
cerebro-endothelial cell morphology and permeability (Hou et al.,
2015). The blockade of SEMA3A signalling may therefore help to
suppress damaging vascular leak in diverse ischemic diseases (see
below, Section 6.2).
4. Functional signiﬁcance of VEGF signalling through NRPs
VEGF is essential for the assembly of blood vessels from single
cell precursors and the expansion of vessel networks through
angiogenesis (reviewed in Ruhrberg, 2003). Accordingly, VEGF is
essential also for retinal vascular development (Haigh et al., 2003)
and drives neoangiogenesis and/or macular oedema in eye pa-
thologies such as PDR, neovascular AMD and BRVO (Nissen et al.,
1998; Saint-Geniez and D'Amore, 2004; Mitry et al., 2013). VEGF
also acts on several non-endothelial cell types, including neurons
(reviewed in Mackenzie and Ruhrberg, 2012). Finally, VEGF plays a
dual role in skin cancer by stimulating angiogenesis through a
paracrine mechanism by signalling via VEGFR2 and by promoting
cancer stem cell renewal through an autocrine, NRP1-dependent
mechanism (Beck et al., 2011). The complexity and versatility of
VEGF signalling is enabled by VEGF's expression in several isoforms
and their binding to several different receptors, which either act
independently of NRP1 or act in co-receptor complexes with NRP1,
as described in the following paragraphs.
4.1. Alternative splicing of VEGF-A isoforms regulates both receptor
and ECM interactions
The presence or absence of the exon 6- and/or 7-encoded pro-
tein domains in the VEGF189 and VEGF165 versus VEGF121 iso-
forms has important functional consequences. These domains
promote NRP binding (see section 1.1) but additionally confer a
high afﬁnity for heparin in vitro that likely reﬂects an ability to bind
heparan sulphate proteoglycans (HSPG) in the extracellular matrix
(ECM) and on the cell surface. In agreement with this idea, VEGF189
has a high afﬁnity for ECM and is therefore poorly diffusible, whilst
VEGF121 is the most diffusible VEGF-A isoform and VEGF165 has
intermediate properties (Houck et al., 1992; Park et al., 1993).
Importantly, these differences translate to a differential ability of
the VEGF isoforms to be retained in the ECM in vivo, with mice
expressing the VEGF120 isoform only at the expense of the other
VEGF isoforms being unable to form proper growth factor gradients
to direct vascular morphogenesis in the brain and retina (Gerhardt
et al., 2003; Ruhrberg et al., 2002). In addition to their distinct
matrix binding afﬁnities, the VEGF isoforms differ in the spectrum
of receptors they bind to (see Section 1.3).
4.2. Signalling pathways induced after VEGF binding to receptor
tyrosine kinases that interact with NRPs
The VEGF121, VEGF165 and VEGF189 isoforms bind to and
activate two tyrosine kinase receptors, VEGFR1 and VEGFR2, with
VEGFR2 being the main receptor that conveys VEGF signals inendothelial cells (Koch et al., 2011).
VEGF binding to VEGFR2 induces receptor homodimerisation
and oligodimerisation, which promotes autophosphorylation on
several tyrosine residues (Y), most notably 951,1054,1175 and 1214,
and these residues then bind intracellular adaptor proteins to
initiate signal transduction (Koch et al., 2011). For example, the
recruitment of SCK and GRB2 adaptor proteins to phosphorylated
VEGFR2 Y1175 enables VEGF-induced ERK1/2 signalling. The role of
NRP1 in modulating VEGFR2 signalling is discussed in detail below
(Section 4.4). VEGF165b has been shown to inhibit VEGF165-
induced VEGFR2 phosphorylation by acting as a competitive
antagonist for VEGF165 in VEGFR2 binding (Woolard et al., 2004).
In contrast to VEGFR2, VEGFR1 is thought to functionmainly as a
decoy receptor in angiogenesis by trapping VEGF to prevent VEGF
binding to VEGFR2 and therefore inhibiting VEGFR2 signalling
(Koch et al., 2011; Rahimi et al., 2000). In support of this idea, the
tamoxifen-inducible knockout of FLT1 in neonatal mice causes
overgrowth of the retinal vasculature, presumably in part by
increasing VEGFR2 levels and in part by increasing VEGF availability
for VEGFR2 activation (Ho et al., 2012). In contrast, the interaction
of VEGFR1with NRP1 appears to be important for VEGFB signalling,
because VEGFB treatment stimulates NRP1-mediated myocardial
angiogenesis and arteriogenesis in ischemic pig myocardium
through VEGFR1 and not VEGFR2 (Lahteenvuo et al., 2009).
In agreement with the observation that NRP2 interacts with
VEGF receptor tyrosine kinases, NRP2 loss reduces both VEGF- and
VEGFC-induced cell survival andmigration in humanmicrovascular
endothelial cells (Favier et al., 2006). In vivo, the interaction be-
tween NRP2 and VEGFR2 is important for developmental lym-
phangiogenesis (Xu et al., 2010), tumour-associated pathological
lymphangiogenesis (Han et al., 2015b) and likely also for corneal
inﬂammatory neovascularisation-associated lymphangiogenesis
(Tang et al., 2015).4.3. Role of NRP1 in modulating VEGF-dependent neural signalling
pathways
VEGF164 signalling through NRP1 has been identiﬁed in three
different types of neurons, facial branchiomotor neurons in the
hindbrain to regulate their cell body migration, gonadotropin-
releasing hormone (GnRH) neurons to ensure their neuro-
protection during their migration from the nasal placode into the
brain, and RGC neurons in the retina to enable their axon guidance
(reviewed in Mackenzie and Ruhrberg, 2012). In particular,
VEGF164 signalling through NRP1 enables the sorting of RGC axons
into the contralateral brain hemisphere at the optic chiasm, a major
diencephalic brain commissure (Erskine et al., 2011). Interestingly,
these VEGF164/NRP1-dependent processes do not require VEGFR2
or VEGFR1, and the NRP1 cytoplasmic domain does not appear to be
required for these processes either, suggesting that NRP1 associates
with unidentiﬁed co-receptors in these cells. VEGF signalling also
promotes the survival of RGC neurons in the adult, but this is likely
mediated by VEGFR2 independently of NRP1, as VEGF120 with a
low afﬁnity for NRP1 is able to activate survival signalling
(Nishijima et al., 2007). Interestingly, conditional knockout studies
suggest that VEGFR2 signalling in RGCs is not required for retinal
morphogenesis (Okabe et al., 2014), while VEGFR2 is instead
required for the survival of Muller glia, which are in turn essential
for the viability of adult retinal neurons in a model of diabetic
retinopathy (Fu et al. Diabetes 2015). Analogous conditional
knockout studies will be required to address whether VEGFR2
signalling is also directly required for adult RGC survival in ageing
adults.
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A role for NRP1 as a co-receptor for VEGFR2 was initially iden-
tiﬁed through studies in porcine aortic endothelial (PAE) cells; thus,
overexpressing NRP1 alongside VEGFR2 increases VEGF165-
induced endothelial cell chemotaxis compared to overexpressing
VEGFR2 alone (Soker et al., 1998). Moreover, the VEGF165-induced
activation of signal transduction cascades involving the ERK1/2 and
p38 MAPK kinases was greater in PAE cells co-expressing NRP1 and
VEGFR2 compared to cells expressing VEGFR2 alone (Becker et al.,
2005). NRP1 alone did not activate these VEGF165-induced path-
ways (Becker et al., 2005; Soker et al., 1998). Treating PAE cells co-
expressing NRP1 and VEGFR2 proteins with a peptide that blocks
VEGF165 binding to NRP1 without affecting VEGF165 binding to
VEGFR2 also reduced VEGFR2 tyrosine phosphorylation and
VEGF165-induced ERK activation, but with a small effect on
VEGF165-induced AKT phosphorylation (Jia et al., 2006). Support-
ing these ﬁndings, treating human umbilical vein endothelial cells
(HUVECs), which endogenously express both VEGFR2 and NRP1,
with anti-NRP1 blocking antibodies reduced VEGFR2 phosphory-
lation and downstream ERK and AKT activation, although did not
abrogate it completely as is instead observed with anti-VEGF anti-
body treatment (Pan et al., 2007a). In cultured embryoid bodies and
in subcutaneous matrigel plugs, VEGF164 also requires NRP1 to
activate p38 MAPK kinase, whose inhibition attenuates angiogen-
esis (Kawamura et al., 2008). In contrast, NRP1 did not promote
VEGF121-induced chemotaxis in PAE cells when overexpressed
alongside VEGFR2 (Soker et al., 1998). Together, these studies sug-
gest that NRP1 is not essential for VEGFR2-induced signalling, but
augments VEGF165-induced, VEGFR2-dependent MAPK signalling.
4.4.1. NRP1 as a regulator of VEGF-dependent arteriogenesis
Arteriogenesis is a process by which small calibre vessels give
rise to functional arteries subsequent to increased ﬂow and hence
increased shear stress, and this process involves VEGF-induced
arterial fate speciﬁcation, lumen expansion and endothelial cell
proliferation (reviewed in Koﬂer and Simons, 2015). During
VEGF165-induced arterial morphogenesis, VEGF165-bound
VEGFR2 activates its downstream effectors ERK1/2 in a mecha-
nism that depends on synectin (Lanahan et al., 2010). NRP1 is
required to bridge VEGFR2 to synectin, as shown in knock-in mice
expressing a mutated NRP1 form lacking the cytoplasmic domain
(Nrp1cyto/cyto mice) (Lanahan et al., 2013). Accordingly, VEGF164-
stimulated endothelial cells of Nrp1cyto/cyto and synectin-null mice
have signiﬁcantly reduced ERK activation, and both types of mu-
tants show impaired arterial branching in the developing heart,
kidney and hindlimb and reduced post-ischemic arteriogenesis in
the hindlimb ischemia model (Lanahan et al., 2010, 2013). Mecha-
nistically, the NRP1 cytoplasmic tail and synectin link VEGFR2 to a
myosin VI-mediated transport machinery that promotes VEGFR2
trafﬁcking into RAB5-positive endosomes, in which VEGFR2 is
protected from PTP1b-mediated dephosphorylation, and this en-
ables sustained ERK activation (Lanahan et al., 2013). Together,
these data suggest that VEGF164 bridges VEGFR2 to NRP1, which
then binds synectin via its cytoplasmic tail to ensure high level ERK
activation for arteriogenesis (Fig. 2).
NRP1 was also shown to promote arterial differentiation
through studies in mice carrying knockin mutations that abrogate
VEGF164 binding to the NRP1 b1 domain, termed Nrp1Y297A/Y297A
and Nrp1D320K/D320K mice (Fantin et al., 2014; Gelfand et al., 2014).
Both types of mutants have impaired arterial differentiation, with
fewer arteries and impaired arterial smooth muscle differentiation
in the retina (Fantin et al., 2014; Gelfand et al., 2014). Thesemutants
also have reduced post-ischemic arteriogenesis in the hindlimbischemia model (Gelfand et al., 2014), similar to mice lacking the
NRP1 cytoplasmic domain (Lanahan et al., 2013).
Despite these functional similarities, there are important dif-
ferences between the two strains of mice with defective VEGF
binding to NRP1. Thus, the insertion of a mutated cDNA into the
endogenous Nrp1 locus reduces overall NRP1 levels in Nrp1Y297A
knockin mutants, in addition to impairing VEGF binding to the
NRP1 b1 domain (Fantin et al., 2014). The combination of these
defects results in a more severe vascular phenotype than in the
subsequently generated Nrp1D320K knockin mutants, which lack
VEGF-binding to NRP1 without lowering overall NRP1 levels
(Gelfand et al., 2014). Thus, Nrp1Y297A/Y297A mutants have subtle
embryonic brain vascular defects that are not observed in
Nrp1D320K/D320K mutants (Fantin et al., 2014; Gelfand et al., 2014).
Accordingly, Nrp1D320K knockin mice with their normal NRP1
expression levels represent a more accurate tool to speciﬁcally
assess the role of VEGF binding to NRP1.
The hearts of Nrp1Y297A/Y297A mice also have fewer coronary ar-
teries and capillaries, similar to Vegfa120/120 mice expressing
VEGF120 only at the expense of the heparin/NRP1-binding VEGF
isoforms; moreover, a small proportion of these Nrp1 mutants die
perinatally, similar to Vegfa120/120 mice that are known to suffer
from ischemic cardiomyopathy (Carmeliet et al., 1999; Fantin et al.,
2014). Whether heart vascularisation is also defective in Nrp1D320K/
D320K mutants has not yet been examined.
VEGF-binding to NRP1 and the NRP1 cytoplasmic domain are
also required to promote the spatial separation of retinal arteries
and veins. In bothNrp1Y297A/Y297A andNrp1cyto/cyto retinas of mice on
a C57/Bl6 background, arteries and veins cross each other at an
abnormally high frequency (Fantin et al., 2011, 2014), as previously
reported for mice with haploinsufﬁcient expression of VEGF in
neural progenitors (Haigh et al., 2003). At these crossing sites, the
artery is positioned anteriorly to the vein, and both vessels are
embedded in a shared collagen sleeve (Fantin et al., 2011). This
morphology is similar to the arteriovenous crossings in human eyes
that were found to be risk factors for BRVO (see above). Nrp1Y297A/
Y297A and Nrp1cyto/cytomice may therefore provide a suitable genetic
model to study the aetiology of BRVO. It has not yet been examined
whether the Nrp1D320K/D320K mutants also have an increased fre-
quency of arterio-venous crossing sites.
Taken together, the above studies in mouse models suggest that
NRP1 is a key regulator of VEGF-dependent arterial morphogenesis
in the developing heart, kidney, hindlimb and eye, and that it also
promotes arteriogenesis in adults.
4.4.2. NRP1 as a regulator of VEGF-dependent angiogenesis
The tissue culture work described above had suggested that
chemotactic VEGF164 signalling through VEGFR2 and therefore
endothelial cell migration are augmented by NRP1. To understand
whether these pathways are important for angiogenesis in vivo,
much work has been carried out in several developmental model
systems. This work initially showed that, during angiogenesis,
endothelial cells sprout from pre-existing vasculature, whereby the
sprouts are composed of stalk cells and led by highly migratory
endothelial cells, termed tip cells (Gerhardt et al., 2003; Ruhrberg
et al., 2002) (Fig. 2). Tip cells extend ﬁlopodia into the extracel-
lular environment and are highly responsive to VEGF, presumably
because they express high levels of VEGFR2 (Gerhardt et al., 2003)
and NRP1 (Fantin et al., 2013a). The importance of NRP1 for tip-cell
led developmental angiogenesis was subsequently characterised in
the zebraﬁsh larval trunk (Bovenkamp et al., 2004; Fantin et al.,
2015; Lee et al., 2002; Martyn and Schulte-Merker, 2004; Yu
et al., 2004), the mouse embryo hindbrain (Fantin et al., 2015;
Gerhardt et al., 2004) and the mouse postnatal retina (Aspalter
et al., 2015; Fantin et al., 2011, 2015; Raimondi et al., 2014). Even
Fig. 2. NRP1 regulates multiple signalling pathways in endothelial cells. In tip cells, NRP1 promotes VEGF- and ECM-signalling to promote sprouting angiogenesis. VEGF signalling
through VEGFR2/NRP1 complexes induces ERK activation for cell proliferation and migration. Additionally, NRP1 activates ABL1 and CDC42 in response to integrin ligands in the
ECM to promote actin remodelling and ﬁlopodia formation to enable cell shape changes. NRP1 also suppresses TGF-b signalling to promote tip cell positioning through a mechanism
that is incompletely understood. In phalanx cells, NRP1 binds synectin and VEGF and forms a complex with VEGFR2 to enable high level ERK signalling for arteriogenesis.
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genesis, only retinal angiogenesis has so far been shown to require
VEGF binding to NRP1 (Fantin et al., 2014; Gelfand et al., 2014).
Supporting the idea that NRP1 is important for ocular vessel
growth, the treatment of mice with antibodies that block VEGF
binding to NRP1 impairs retinal angiogenesis (Pan et al., 2007a).
To deﬁne roles for NRP1 in retinal angiogenesis, two genetic
tools have been employed that circumvent the embryonic lethality
of full Nrp1 knockout mice; tamoxifen-inducible, endothelial NRP1
knockout mice (Aspalter et al., 2015; Fantin et al., 2015; Raimondi
et al., 2014) and mice with point mutations that impair VEGF
binding to NRP1 (see above, section 1.3) (Fantin et al., 2014; Gelfand
et al., 2014). To generate inducible, endothelial NRP1 knockouts for
retinal angiogenesis studies, mice with conditional Nrp1-null
(ﬂoxed) alleles (Nrp1ﬂ/ﬂ) were crossed to mice expressing a
tamoxifen-inducible Cre transgene under the control of the endo-
thelial Pdgfb promoter (Pdgfb-iCreER-Egfp (Fantin et al., 2015;
Raimondi et al., 2014). Tamoxifen-treated littermate mice
expressing or lacking Cre from P2 to P5 showed that NRP1 loss
impairs the radial extension of the superﬁcial vascular plexus and
decreases the vascular network density (Fig. 3A) (Fantin et al., 2015;
Raimondi et al., 2014). Furthermore, these studies showed that
NRP1 loss severely reduces the number of morphologically iden-
tiﬁable tip cells, vessel sprouts at the vascular front and lateral
connections between sprouting vessels (Fantin et al., 2015;
Raimondi et al., 2014). Defective radial outgrowth of the retinalvasculature was also seen in mice lacking VEGF binding to NRP1
(Fantin et al., 2014, 2015; Gelfand et al., 2014). It is likely that these
VEGF-dependent roles of NRP1 operate in tip cells and involve the
ERK and p38 pathways previously identiﬁed in embryoid body and
tissue culture models (Fig. 2). However, with endothelial ERK1/2
mutants and p38-mutants not yet analysed, formal proof of this
role is still lacking.
In contrast to radial vascular outgrowth, vascular network
density was not affected in mice lacking VEGF binding to NRP1
(Fantin et al., 2014, 2015; Gelfand et al., 2014). The sparse vascular
plexus in tamoxifen-inducible endothelial NRP1 knockout mice
was better explained by the loss of ECM signalling via NRP1 (see
section 5.1) (Fantin et al., 2015). Thus, the important role for NRP1
in angiogenesis is only partly explained by its ability to bind
VEGF164. The multiple VEGF-independent roles for NRP1 in retinal
angiogenesis are discussed in Section 5.
4.5. NRP1 as a regulator of VEGF-induced hyperpermeability
VEGF was originally discovered as a tumour-secreted vascular
permeability factor due to its ability to induce the accumulation of
ascites (Senger et al., 1983). In particular, VEGF opens the endo-
thelial barrier that normally prevents plasma extravasation into the
tissue surrounding the blood vessel. Because VEGF regulates
vascular permeability in addition to promoting angiogenic and
arteriogenic blood vessel growth, the therapeutic potential to
Fig. 3. NRP1 promotes physiological and pathological angiogenesis in the retina. (A) P6 retinal vasculature in Pdgfb-iCreERT2;Nrp1ﬂ/ﬂ mice and control mice lacking Cre after
tamoxifen injection from P2 to P5 and immunolabelling for NRP1 together with IB4. Red arrows indicate the larger distance from the vascular front to the retinal periphery in Pdgfb-
iCreERT2;Nrp1ﬂ/ﬂ mutants (upper panels). Higher magniﬁcations of the vascular front areas indicated by boxes in the upper panels are shown in the middle panels; D indicates
reduced lateral connections in the vasculature of mutants. The bottom panels show reduced NRP1 expression in the retinal vasculature of Pdgfb-iCreERT2;Nrp1ﬂ/ﬂ mutants compared
to controls (asterisks), conﬁrming efﬁcient gene deletion. (B) P17 retinas from Pdgfb-iCreERT2;Nrp1ﬂ/ﬂ mice and control littermates lacking Cre in the OIR model after tamoxifen
injection from P13 to P16 after return from hyperoxia to normoxia; retinas were immunolabelling for NRP1 and collagen IV together with IB4. The avascular area is outlined in red in
the lowmagniﬁcation images in the upper panels, which show the IB4 staining only. Higher magniﬁcation of the boxed areas are shown in the middle panels with IB4 together with
collagen IV staining to illustrate reduced neovascular tuft formation in Pdgfb-iCreERT2;Nrp1ﬂ/ﬂmutants compared to control. The bottom panels show reduced NRP1 expression in the
retinal vasculature of Pdgfb-iCreERT2;Nrp1ﬂ/ﬂ mutants. Scale bars: 1 mm (A,B).
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of hyperpermeability that might cause tissue injury and oedema.
Research elucidating the molecular mechanism that steers VEGF-
induced responses of vascular endothelial cells towards angiogen-
esis versus vascular permeability might therefore identify targets
suitable for the selective manipulation of VEGF responses in
vascular eye disease.
Even though some studies implicated VEGFR2 as the main VEGF
receptor that conveys endothelial permeability signalling (Bates
and Harper, 2002; Murohara et al., 1998; Sun et al., 2012), several
other lines of evidence suggest that NRP1 also contributes to VEGF-
induced vascular hyperpermeability, albeit through an incom-
pletely understood mechanism. Initially, in vitro experiments
showed that the transendothelial electrical resistance (TEER) of PAE
cells co-transfected with NRP1 and VEGFR2 decreased after
VEGF165 stimulation, whereas it was unaltered in PAE cells trans-
fected with NRP1 or VEGFR2 alone (Becker et al., 2005). As a low
TEER indicates a propensity for vascular leak, these experiments
raised the possibility that neither VEGFR2 nor NRP1 alone are
sufﬁcient to induce vascular leakage. However, these experiments
were conducted in cells that do not have endogenous VEGF re-
ceptors and therefore lack essential characteristics of true endo-
thelial cells. It is therefore interesting that function-blocking
antibodies for NRP1 inhibit VEGF165-induced permeability inprimary pulmonary endothelial cells, whilst function-blocking an-
tibodies for VEGFR2 did not affect permeability, even though they
abolished VEGF-induced chemotaxis (Becker et al., 2005).
Whilst some in vivo studies support the idea that NRP1 has a
central role in VEGF165-induced vascular permeability, others
found it not to be important. Thus, one study reported that the
genetic deletion of NRP1 in endothelial cells impairs skin perme-
ability after intradermal injection of SEMA3A or VEGF164 (Acevedo
et al., 2008). However, another study reported normal VEGF165-
induced vascular permeability in the retina of endothelial NRP1
knockout mice, even though these mice had defective SEMA3A-
induced permeability (Cerani et al., 2013). These observations raise
the possibility that the NRP1 contribution to VEGF-induced
permeability is context dependent.
Opposing results have also been reported in studies testing the
effect of NRP1-blocking antibodies on VEGF-induced permeability.
Two studies using the same NRP1-blocking antibody showed that
antibody treatment has no effect on VEGF164-induced vascular
permeability in mouse skin (Acevedo et al., 2008; Pan et al., 2007a),
whereas a different NRP1-blocking antibody inhibited VEGF164-
mediated permeability in the mouse skin (Teesalu et al., 2009). It
is not known whether these opposing results can be explained by
the different effectiveness of function-blocking antibodies in
reducing NRP1-mediated vascular permeability depending on the
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In agreement with a NRP1 role in VEGF-induced permeability, a
heptapeptide that blocks VEGF binding to NRP1 (see Section 6.1.2)
attenuates both neovascularisation and vascular permeability in a
mouse model of diabetic retinopathy (Wang et al., 2015a). More-
over, soluble NRP1 expression in mouse skin strongly reduces
vascular leakage induced by intradermal VEGF injection (Mamluk
et al., 2005), perhaps because it acts as a VEGF164 trap.5. VEGF- and SEMA3A-independent NRP1 signalling pathways
in the vasculature
Constitutive NRP1 knockout mice are embryonically lethal with
vascular defects in the yolk sac, spinal cord and brain (Fantin et al.,
2013a; Gerhardt et al., 2004; Jones et al., 2008; Kawasaki et al.,
1999), and they also have defective remodelling of the large ves-
sels of the heart (Kawasaki et al., 1999; Plein et al., 2015a). However,
NRP1 function in angiogenesis has been best studied in the mouse
embryo hindbrain and led to the demonstration that NRP1 is
essential for endothelial tip cell function and that it promotes
angiogenesis in VEGF-independent pathways (Fantin et al., 2014,
2015, 2013a; Gerhardt et al., 2004). In the mouse, vessels sprout
from the perineural vascular plexus into the hindbrain at E9.5 and
then grow towards the ventricular zone, attracted by VEGF secreted
from neural progenitors (Breier et al., 1992; Haigh et al., 2003;
Ruhrberg et al., 2002). From E10 onwards, radial vessels extend
sprouts at near right angles to extend beneath the ventricular
hindbrain surface, forming the subventricular vascular plexus (SVP)
following anastomosis of neighbouring sprouts (Fantin et al., 2010).
Whilst the SVP begins to form from E10.5 onwards in wildtype
mice, heterozygous Nrp1-null hindbrains have a less dense SVP, and
homozygous Nrp1-null hindbrains lack an SVP at this stage entirely
(Fantin et al., 2015). Thus, NRP1 promotes hindbrain vascularisation
in a dose-dependent manner.
Whereas vascular ingression largely recovers in heterozygous
Nrp1 mutant hindbrains, the radial vessels that enter homozygous
Nrp1-null hindbrains terminate in dead-ended vessel tufts rather
than a branched network (Fantin et al., 2015; Gerhardt et al., 2004).
This defect is phenocopied in mouse mutants lacking NRP1 spe-
ciﬁcally in endothelium, whereas NRP1 expression by neural pro-
genitors and tissue macrophages in the vascular environment is
dispensable for hindbrain vascularisation (Fantin et al., 2013a).
Recent genetic mosaic analyses of hindbrain blood vessels
demonstrated a key role for NRP1 in endothelial tip cells by
showing that NRP1 loss prevents endothelial cells from attaining
the tip position (Fantin et al., 2013a).
Although it was originally thought that vascular defects in
NRP1-deﬁcient mice were caused by impaired VEGF signalling
through endothelial NRP1 (e.g. Gu et al., 2003), mice with the
knock-in Y297A mutation that abrogates VEGF binding to NRP1
(Herzog et al., 2011) have only a mild vascular phenotype in the
hindbrain vasculature (Fantin et al., 2014). Moreover, this mild
defect was distinct to the severe phenotype of full NRP1 knockouts
and likely due to a reduction in overall NRP1 levels caused by the
mutant allele (Fantin et al., 2014), rather than defective VEGF
binding to NRP1, as subsequent work with mice carrying a D320K
mutation that does not affect NRP1 expression showed normal
brain angiogenesis in the absence of VEGF binding to NRP1
(Gelfand et al., 2014). NRP1 can therefore promote angiogenesis by
regulating VEGF-independent pathways, and these pathways,
whilst particularly important for embryonic angiogenesis, likely
also contribute to postnatal angiogenesis, as discussed in the
following sections.5.1. NRP1 as a modulator of extracellular matrix signalling in the
vasculature
Several studies have identiﬁed functional interactions of NRP1
with integrin-mediated pathways. Human endothelial cells in vitro
require NRP1 for integrin-mediated adhesion to low concentrations
of integrin ligands such as ﬁbronectin (Murga et al., 2005;
Valdembri et al., 2009). Moreover, NRP1 promotes ﬁbronectin
ﬁbrillogenesis in arterial endothelial cells in vitro by regulating
intracellular trafﬁcking of activated a5b1 in a mechanism that re-
quires the NRP1 cytoplasmic domain (Valdembri et al., 2009). This
pathway was originally proposed to modulate angiogenesis. How-
ever, the NRP1 cytoplasmic domain is not required for angiogen-
esis, but instead promotes arteriogenesis in vivo (Fantin et al., 2011;
Lanahan et al., 2013). Further work is therefore required to establish
whether NRP1-modulated, integrin-driven ﬁbronectin assembly is
important for arteriogenesis. NRP1 also facilitates ﬁbronectin ﬁbril
assembly in the tumour microenvironment, promoting desmo-
plasia (Yaqoob et al., 2012). In this process, the NRP1 cytoplasmic
domainwas shown to recruit the intracellular kinase ABL1 (Yaqoob
et al., 2012), a known integrin interactor (Lewis et al., 1996).
Together, these observations suggest that NRP1 plays important
roles in integrin-mediated matrix remodelling.
In agreement with an important role for NRP1 in integrin sig-
nalling, we recently showed that NRP1 promotes endothelial cell
migration in response to ﬁbronectin (Fantin et al., 2015; Raimondi
et al., 2014). This pathway differed from previously identiﬁed
NRP1-mediated mechanisms in angiogenesis, because it was
functional at ﬁbronectin concentrations that do not challenge
endothelial cell adhesion and operates independently of NRP1's
conventional role as a co-receptor in the VEGF/VEGFR2 pathway.
Instead, this pathway involves the activation of two proteins that
promote actin cytoskeleton remodelling, ABL1 (Raimondi et al.,
2014) and the small RHO-GTPase CDC42 (Fantin et al., 2015) (Fig. 2).
Initially, in vitro studies with human primary endothelial cells
showed that NRP1 forms a complex with ABL1 and stimulates
phosphorylation of paxillin in response to ﬁbronectin stimulation
(Raimondi et al., 2014) (Fig. 4). As ABL1 is known to phosphorylate
paxillin (Lewis and Schwartz, 1998) and paxillin phosphorylation is
important for focal adhesion turnover during cell migration
(Zaidel-Bar et al., 2007), this study provided the ﬁrst mechanistic
explanation why NRP1 is important for endothelial cell migration.
Even though tumour studies had shown that the NRP1 cytoplasmic
domain is important for ABL1 function in ﬁbronectin ﬁbrillo-
genesis, the NRP1 cytoplasmic domain is not required for angio-
genesis (Fantin et al., 2011). It is likely that ABL1 kinase can be
recruited to NRP1-containing multiprotein complexes through
other interactions that may be involve integrins, as NRP1 interacts
with integrins (Fukasawa et al., 2007; Robinson et al., 2009), and
integrins interact with ABL kinases (Lewis and Schwartz, 1998).
A subsequent study from our lab showed that NRP1-mediated
ABL1 signalling is also required for ﬁbronectin-induced activation
of CDC42 (Fantin et al., 2015). CDC42 is a small RHO-GTPase that
cycles between a GTP-bound active and a GDP-bound inactive state
to regulate actin cytoskeleton remodelling, ﬁlopodia extension and
directional migration in various cell types (Heasman and Ridley,
2008), including endothelial cells (Abraham et al., 2015; Fantin
et al., 2015; Wakayama et al., 2015). In particular, NRP1/ABL1-
mediated CDC42 activation promotes the extension of ﬁlopodia as
well as cell shape changes for cell migration in response to ECM
stimulation (Fantin et al., 2015). However, the speciﬁc mechanism
bywhich ABL1 kinase can enable CDC42 activation has not yet been
determined.
ECM-driven, NRP1-dependent actin remodelling promotes both
physiological and pathological angiogenesis in the mouse (Fantin
Fig. 4. NRP1 downregulation and Imatinib treatment similarly inhibit actin cytoskel-
eton remodelling and reduce paxillin phosphorylation. HDMEC transiently transfected
with non-targeting or NRP1-targeting siRNA or treated with 10 mM Imatinib were
seeded on ﬁbronectin for 4 h and immunoﬂuorescently labelled for pPXN Y118 (red)
together with the F-actin marker phalloidin (green). The single channel for pPXN
staining is shown on the right hand side. Scale bar 20 mm.
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developing retinal vasculature of inducible, endothelial speciﬁc
NRP1 knockout mice had fewer tip cells and branchpoints (Fig. 3),
and this defect was phenocopied in mice treated with the ABL ki-
nase inhibitor Imatinib or the CDC42 inhibitor ML141 (Fantin et al.,
2015; Raimondi et al., 2014). Consequently, the primary vascular
plexus of mice lacking ECM-mediated NRP1 signalling via ABL1 and
CDC42 appeared greatly underdeveloped. In agreement with the
inhibitor studies, the genetic deletion of CDC42 in postnatal retinal
vessels reduces ﬁlopodia formation and leads to aberrant vascular
sprouting and remodelling (Barry et al., 2015).
Imatinib-treatment additionally causes a small decrease in
vascular extension of the primary plexus across the developing
retina (Raimondi et al., 2014). This phenotype is likely explained by
reduced ﬁbronectin deposition at the vascular front (Raimondi
et al., 2014), because it was recently shown that loss of ﬁbro-
nectin expression in astrocytes causes a small delay in retinal
vascular extension (Stenzel et al., 2011). Importantly, NRP1mutants
have a more severe reduction in vascular extension than Imatinib-
treated mice, in agreement with an additional role of NRP1 in
promoting chemotactic VEGF signalling through VEGFR2 in endo-
thelial tip cells during retinal vascularisation (Fantin et al., 2014,
2015; Gelfand et al., 2014) (Fig. 2). Thus, NRP1 plays a dual role inangiogenesis by independently promoting ECM-stimulated and
growth factor-induced signals in EC in physiological retinal angio-
genesis (Fig. 2). Both NRP1 roles are also important for pathological
retinal angiogenesis (Section 6).
Despite ample evidence that NRP1 helps to convey extracellular
matrix signals by modulating integrin function, the molecular
mechanism by which NRP1 interacts with integrins is not yet un-
derstood. In particular, it remains to be examined whether NRP1
interacts with integrin b1 directly, or if their interaction is only
indirect as part of a multiprotein complex. Moreover, it is not yet
clear how the VEGF- and ECM-driven NRP1 pathways described
above intersect with NRP1-mediated TGFb signalling, discussed in
the next section.
5.2. NRP1 in TGFb signalling during vascular development
The TGFb family of secreted cytokines regulates cell prolifera-
tion, migration, differentiation and apoptosis. Three TGFb isoforms
exist, produced by the TGFB1, TGFB2 and TGFB3 genes. Each TGFB
gene encodes a pro-protein of 50 kDa, which is cleaved by furin
enzymes and then dimerises; the cleaved dimer binds to the
dimeric pro-protein, also referred to as latency-associated peptide
(LAP), through non-covalent interaction. Upon secretion, the LAP/
TGFb complex is covalently linked to the latent TGFb binding pro-
tein (LTBP) via a disulﬁde bond tomaintain TGFb in an inactive state
(Taylor, 2009). Studies in T-cells revealed that NRP1 binds to active
TGFb1, LAP and the latent form of TGFb that consists of a complex
between TGFb1 and LAP (Glinka and Prud'homme, 2008). It was
also shown that VEGF165 competes with LAP and TGFb1 for NRP1
binding in these cells, suggesting that the NRP1 binding sites for
VEGF165 and TGFb1 overlap (Glinka and Prud'homme, 2008).
NRP1 and NRP2 form a complex with the TGFb receptors
TGFBR1 and TGFBR2, independently of TGFb1 binding. The TGFBR1
can either be ALK1 and ALK5. Studies in breast cancer cells showed
that NRP1 and NRP2 have a similar afﬁnity for TGFBR1, whereas
NRP2 has a higher afﬁnity for TGFBR2 that TGFBR1 (Glinka et al.,
2011). In these cells and also in cardiomyocytes, NRP1 down-
regulation reduces TGFb-dependent phosphorylation of the signal
transducer SMAD2, indicating that NRP1 can positively regulate
TGFb signalling (Rizzolio and Tamagnone, 2011). In agreement, loss
of NRP1 expression speciﬁcally in smooth muscle cells and car-
diomyocytes decreased survival in mice and correlated with car-
diomyopathy (Wang et al., 2015b).
TGFb signalling is crucial for early vascular development, with
50% of Tgfb1-null mice showing defective yolk sac vasculogenesis
and haematopoiesis (Dickson et al., 1995). It has not yet been
examined whether NRP1 is involved in regulating these early TGFb
signalling events. In contrast, a role for NRP1 in modulating TGFb
signalling has been identiﬁed in postnatal angiogenesis. Thus,
NRP1-deﬁcient endothelial cells have increased TGFb signalling and
show hyperphosphorylation of SMAD effectors, which impairs tip
cell formation and therefore sprouting angiogenesis in the post-
natal retina (Aspalter et al., 2015) (Fig. 2). In particular, VEGF-
dependent, but NRP1-independent upregulation of DLL4 in tip
cells activates notch signalling in stalk cells, which in turn de-
creases NRP1 levels in stalk cells, thus relieving the inhibition of
SMAD-dependent signalling and thereby promoting stalk cell
behaviour (Aspalter et al., 2015). The defective ability of NRP1-
deﬁcient cells to reach the tip position can be rescued by the
endothelial deletion of one copy of either ALK1 or ALK5 (Aspalter
et al., 2015). Also agreeing with a role for NRP1 in suppressing
endothelial TGFb signalling, NRP1 forms an intercellular protein
complex with b8 integrin on neuroepithelial cells that promotes
cellecell adhesion between endothelial and neuroepithelial cells
and balances TGFb signalling via SMAD effectors (Hirota et al.,
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TGFb signalling in endothelial cells versus smooth muscle or cancer
cells.
5.3. NRP1 in PDGF signalling in smooth muscle cells
NRP1 can modulate signalling induced by the platelet-derived
growth factor PDGFA and PDGFB. As mentioned above, NRP1 in-
teracts with PDGFRs, and NRP1 downregulation reduces PDGF-
induced PDGFR phosphorylation and therefore cell migration and
proliferation of human mesenchymal stem cells (Ball et al., 2010).
NRP1 also forms a constitutive complex with PDGFRa in primary
human aortic smooth muscle cells, stimulating PDGFR phosphor-
ylation and the PDGF-dependent phosphorylation of the adapter
protein p130Cas (Crk-associated substrate) to increase smooth
muscle cell migration (Evans et al., 2011; Pellet-Many et al., 2011). A
recent study reported that NRP1 expression in smooth muscle cells
does not play major roles in the development or the maturation of
the aorta or retinal arteries; instead, NRP1 preserves smooth
muscle contractility and motility in the gastrointestinal tract
(Yamaji et al., 2015). However, further in vivo studies are required to
establish whether lack of PDGF signalling is responsible for the
defective function of visceral smooth muscle lacking NRP1. It also
remains to be investigated whether PDGF enables bridge formation
between NRP1 and PDGF receptors to increase signal transduction
in a mechanism akin to that induced by VEGF165 during NRP1-
VEGFR2 complex formation and signalling (see above).
6. NRP1 as a therapeutic target in neovascular eye disease
We recently reported that NRP1 is expressed in the endothelial
cells of neovascular lesions in the OIR model (Fig. 3B) (Raimondi
et al., 2014). Moreover, we demonstrated that the tamoxifen-
inducible, endothelial speciﬁc ablation of NRP1 in postnatal mice
impaired the revascularisation of vasoobliterated areas and
reduced the formation of neovascular lesions in this model (Fig. 3B)
(Raimondi et al., 2014). Interestingly, endothelial NRP1 targeting
caused a slightly stronger effect than Imatinib treatment, which
blocks ABL1 as a downstream effector of NRP1 in ECM signalling
(Raimondi et al., 2014). This observation raises the possibility that
NRP1 has a dual role promoting ECM-stimulated and VEGF-induced
signals in endothelial cells in OIR, as observed during physiological
angiogenesis (see above). A dual role for NRP1 in VEGF- and ECM-
driven angiogenesis during pathological angiogenesis may also
explain why anti-VEGF and anti-NRP1 treatments have an additive
effect in reducing tumour growth (Pan et al., 2007a). However,
these ideas remain to be tested experimentally.
NRP1 is expressed by both endothelial cells and RPE cells in
choroidal neovascular membranes of AMD patients (Lim et al.,
2005). Agreeing with a role for NRP1 in neovascular AMD, a
single-nucleotide polymorphism (SNP) in NRP1 (rs2070296) is
associated with decreased response to ranibizumab (Lucentis), as
assessed by treatment-induced improvement of visual acuity
(Lores-Motta et al., 2016). The cause of this association is unlikely to
be a change in protein sequence as this variant represents a syn-
onymous mutation at position 537 in the cDNA sequence (http://
www.ensembl.org/Homo_sapiens/Transcript/Sequence_cDNA?
db¼core;g¼ENSG00000099250;r¼10:33177492-33336262;
t¼ENST00000374867). Moreover, this SNP does not appear to be in
linkage-disequilibrium with any other known coding SNPs (link-
age-disequilibrium data from the 1000 Genomes Project). It has not
yet been examined whether this SNP is associated with regulatory
elements that control gene expression.
The importance of NRP1 in animal models of vascular pathology
and tumourigenesis, combined with multiple descriptions of NRP1expression in human disease, suggests that NRP1 may be a useful
therapeutic target for several vessel-associated diseases. NRP1
function may be inhibited with function blocking antibodies, pep-
tides, small molecules or micro RNA (miRNA) mimics. Most studies
seeking to target NRP1 function have assessed a candidate agent's
ability to modulate endothelial cell phenotypes in commonly used
in vitro assays and/or examined their ability to inhibit tumour
growth and angiogenesis in mouse models. Many of the principle
ﬁndings obtained through these studies will likely be relevant for
ocular disease. The search for NRP1 blocking agents has so far
focussed mainly on identifying compounds that inhibit VEGF164
binding to NRP1, but recent studies raised the possibility that VEGF-
independent NRP1 functions may also be possible therapeutic
targets, such as manipulating SEMA3A signalling through NRP1 or
NRP1-mediated ECM signalling via integrins.6.1. Agents that target VEGF binding to NRP1
6.1.1. Monoclonal antibodies that target NRP1
Genentech utilised a synthetic, naïve-antibody phage library to
develop NRP1 function-blocking antibodies (Liang et al., 2007).
They subsequently characterised two of these agents in detail, anti-
NRP1A, which targets the NRP1 a1-a2 domains to inhibit SEMA3A
binding, and anti-NRP1B, which targets the b1-b2 domain to inhibit
VEGF164 binding (Pan et al., 2007a). The dissociation constants (Kd)
of anti-NRP1A and anti-NRP1B are 0.9 nM and 0.4 nM for human
NRP1, respectively, and both antibodies also bind mouse NRP1 (Pan
et al., 2007a). Although anti-NRP1A and anti-NRP1B target distinct
NRP1 domains and prevent binding to different ligands, both are
capable of inhibiting VEGF164-dependent endothelial cell migra-
tion and angiogenic sprouting in vitro (Pan et al., 2007a). In fact,
each antibody is capable of preventing the formation of the
VEGF164-induced NRP1-VEGFR2 complex, thereby explaining why
both antagonise endothelial VEGF164 signalling (Pan et al., 2007a).
In agreement, both antibodies inhibit corneal neovascularisation in
rats and impair retinal vascular remodelling in mice (Pan et al.,
2007a). In neonatal mice, the combined anti-VEGF and anti-
NRP1B treatment decreases retinal vascular density more than anti-
VEGF treatment alone (Pan et al., 2007a). This observation raises
the possibility that each reagent alone is either suboptimal at tar-
geting VEGF signalling, or that anti-NRP1B, even though designed to
target VEGF-dependent pathway, also targets VEGF-independent
pathways.
MNRP1685A is a phage-derived monoclonal antibody equiva-
lent to NRP1B that recognises NRP1 in humans as well as mice, rats
and monkeys (Xin et al., 2012a) and has been evaluated in human
phase I studies of solid tumour growth to deﬁne its pharmacoki-
netics, pharmacodynamics and safety proﬁle (Weekes et al., 2014;
Xin et al., 2012b). The synergistic effect of anti-NRP1B and anti-
VEGF in mouse models of ocular neovascularisation (Pan et al.,
2007a) provided the rationale for a further phase 1b trial of
MNRP1685A (Patnaik et al., 2014). This trial assessed the safety of
treating patients afﬂicted by advanced tumours with MNRP1685A
together with Bevacizumab, a humanised monoclonal antibody
that inhibits VEGF and has been approved for the treatment of
several types of cancer. Disappointingly, high rates of proteinuria
were observed, exceeding those observed with Bevacizumab alone,
suggesting that further clinical trials with the combination therapy
were not warranted (Patnaik et al., 2014). It has not yet been
investigated whether the combined treatment might instead be
effective to treat eye disease, for which the intravitreal delivery of
therapeutics would likely reduce the risk of systemic adverse ef-
fects such as proteinuria. Moreover, MNRP1685A has not yet been
tested for efﬁcacy as a single agent to treat neovascular eye disease.
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Several different types of NRP1-targeting peptides are available
that differ in their design, but have the common purpose of tar-
geting the VEGF binding domain of NRP1.6.1.2.1. C-end rule peptides. Phage display screens for inducers of
cell internalisation and tissue penetration identiﬁed a class of
peptides with a R/K/XXR/K C-terminal motif that were capable of
binding NRP1 and subsequently termed C-end rule (CendR) pep-
tides (Teesalu et al., 2009). The CendR motif is endogenously pre-
sent at the C-terminus of VEGF and in several semaphorins after
furin cleavage (Parker et al., 2013; Teesalu et al., 2009). The RPAR-
PAR peptide was the ﬁrst CendR peptide studied in detail, because
of its ability to induce NRP1 internalisation and vascular perme-
ability (Teesalu et al., 2009). Different combinations of the central
‘XX’ amino acids of the CendRmotif have since been examined, and
it was concluded that several combinations are sufﬁcient for NRP1
binding, but that PA, PP or PR residues in the XX position are
optimal (Zanuy et al., 2013). The CendR peptides appear to be most
effective when assembled into multimers, likely because the Kd of
each individual peptide is low, being in the micromolar range, or
because multivalent ligands are required for receptor oligomer-
isation (Teesalu et al., 2009). Aside frommodulating NRP1 function,
CendR peptides have been proposed as useful agents for delivering
cargo into endothelial and tumour cells, as they can be chemically
coupled to other molecules and undergo NRP1-mediated endocy-
tosis (Sugahara et al., 2009).6.1.2.2. A7R. The heptapeptide ATWLPPR (A7R) was originally
thought to antagonise the VEGF interaction with VEGFR2
(Binetruy-Tournaire et al., 2000), but is now known to impair VEGF
binding to NRP1 (Starzec et al., 2006). With a C-terminal arginine
residue, this sequence resembles a C-end rule peptide, and with
prolines in the XX position, this peptide has the correct motif for
high NRP1 afﬁnity (Zanuy et al., 2013). The C-terminal LPPR
sequence in particular was found to be essential for antagonising
the interaction of VEGF with NRP1 (Starzec et al., 2007). A7R re-
duces endothelial cell proliferation and tube formation in matrigel-
based ﬁbroblast co-culture assays in vitro. In vivo, A7R adminis-
tration reduces vascular density and tumour size in a breast cancer
cell xenograft model, but has no direct effect on cancer cell prolif-
eration (Starzec et al., 2006). The vascular effects of A7R treatment
are not limited to angiogenesis. The peptide can prevent VEGF-
induced vascular permeability in a mouse model of VEGF-
mediated neuroinﬂammation (Suidan et al., 2012), and, within
the context of ocular disease, A7R treatment has recently been
suggested to prevent blood-retinal barrier dysfunction in a diabetic
mouse model (Wang et al., 2015a).6.1.2.3. Bicyclic peptides. Bicyclic peptides are polypeptides with
two circular units. They tend to have higher speciﬁcity for their
targets and are more resistant to circulating proteases than linear
peptides (Baeriswyl and Heinis, 2013). EG3287 is a bicyclic peptide
that is designed upon the sequence encoded by exons 7 and 8 of
VEGF and is cyclised through disulﬁde bonding (Jia et al., 2006).
Although cyclised, the folding of EG3287 resembles that of the
VEGF C-terminus, as demonstrated by nuclear magnetic resonance
(NMR) (Jia et al., 2006). EG3287 antagonises VEGF binding to NRP1
expressed by PAECs with an IC50 of 3 mM, but has no antagonistic
effect on VEGF binding to VEGFR1- or VEGFR2-expressing PAECs
(Cheng et al., 2004). Furthermore, EG3287 prevents the formation
of the VEGFR/VEGF/NRP1 complex and VEGFR2 phosphorylation
(Jia et al., 2006).6.1.3. Small molecule inhibitors of NRP1
Small molecule inhibitors can be produced with greater cost-
effectiveness and have superior pharmacokinetic properties
compared to peptide-based agents. Accordingly, several studies
have attempted to identify small molecule inhibitors of the VEGF-
NRP1 interaction. The earliest of these endeavours was a com-
mercial screen of a small molecule library that identiﬁed 3-amino-
1-cyano-indolizines as potent inhibitors of the VEGF-NRP1 inter-
action. The most potent of these molecules inhibited VEGF-NRP1
binding with an IC50 of 2 mM (Bedjeguelal et al., 2006). However,
published evidence is not available to determine whether these
compounds inhibit VEGF-induced angiogenesis, and it is not known
if they may be useful in preclinical or clinical settings.
The VEGF-NRP1 binding antagonist termed EG00229 is a small
molecule inhibitor based upon the previously described EG3287
bicyclic peptide (Jarvis et al., 2010). NMR and crystallography data
demonstrated that this compound binds the VEGF-binding pocket
of NRP1 (Jarvis et al., 2010). EG00229 inhibited VEGF binding to
NRP1 in a cell free assaywith an IC50 of 3 mMand in HUVECswith an
IC50 of 23 mM, whereby the reduced potency in the cell assay is
likely explained by the presence of the alternative VEGF receptors
VEGFR1 and VEGFR2, which are not targeted by EG00229 (Jarvis
et al., 2010). This compound showed promising results in impair-
ing VEGF-induced migration in HUVECs, and a recent in vivo study
suggested that it may also be suitable for NRP1 targeting when
delivered locally via a minipump (Miyauchi et al., 2016).
Themost recent small molecule antagonists of VEGF164 binding
to NRP1were identiﬁed using an in silico approach, inwhich a small
molecule library was screened for compounds that held a structure
likely to ﬁt the VEGF binding pocket of NRP1. Candidates were
subsequently validated as inhibitors of VEGF-binding to NRP1 and
of HUVEC proliferation (Borriello et al., 2014). The lead candidate N-
[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-N’-(2,3-dihydro-1,4-
benzodioxin-6-ylcarbonyl)thiourea had a higher potency in inhib-
iting HUVEC proliferation than EG00229 (IC50 ¼ 0.2 mM compared
to an IC50¼ 160 mM for EG00229), even though it was less potent in
blocking VEGF binding to NRP1 (IC50 ¼ 34 mM compared to
IC50¼ 16 mM for EG00229) (Borriello et al., 2014). Furthermore, this
compound had demonstrable anti-angiogenic properties in an
in vitro tubulogenesis assay and a tumour xenograft model
(Borriello et al., 2014). However, the drastic reduction in tubulo-
genesis or angiogenesis correlated with signiﬁcant levels of
apoptosis in both models, suggesting that this compound might be
more suitable for tumour targeting than the treatment of neo-
vascular eye disease.
6.2. Targeting VEGF-independent NRP1 pathways
6.2.1. Therapeutic potential of targeting SEMA3A signalling through
NRP1
Based on work in the OIR mouse model, it has been proposed
that exogenous SEMA3A may be administered to redirect neo-
vascularisation from the vitreous into the retina in retinopathies
(Joyal et al., 2011) (see Section 3.3). In effect, this type of therapeutic
approach would seek to neutralise the harmful effects of intra-
retinal endogenous SEMA3A with a counter-gradient of exogenous
SEMA3A. However, it has not yet been examined if this strategy
induces vascular leak. This is an important consideration, given the
ﬁnding that SEMA3A induces retinal oedema in a mouse model of
PDR and the observed upregulation of SEMA3A in the retina during
the early hyperglycaemic phase in diabetic patients with macular
oedema (Cerani et al., 2013) (see Sections 3.3 and 3.4).
Alternatively, and analogous to a SEMA3A knockout, blockade of
endogenous, intraretinal SEMA3A signalling might also prevent
repulsion of vessels from the neuroretina into the vitreous and
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oedema. As SEMA3A does not play any known role in vascular
maintenance, this strategy may not suffer from impaired chorio-
capillaris maintenance, as may be the case for long-term anti-VEGF
therapy. Moreover, SEMA3A is pro-apoptotic for endothelial cells
in vitro (Guttmann-Raviv et al., 2007; Klagsbrun and Eichmann,
2005), raising the possibility that SEMA3A blockade might also
promote endothelial survival in diseases with vascular drop-put,
such as diabetic retinopathy. In addition to providing signals to
endothelial cells in vascular eye pathology, SEMA3A was also
hypothesised to promote the recruitment of myeloid cells as well as
myeloid cell-mediated pathological neovascularisation in the OIR
model (Dejda et al., 2014). However, the relative importance of
SEMA3A and VEGF164 for the attraction and function of NRP1-
expressing myeloid cells was not functionally distinguished in
this study.
Future work is clearly required to establish whether targeting
SEMA3A signalling would be beneﬁcial to treat neovascular eye
disease, and whether exogenous delivery or blockade of endoge-
nous SEMA3A is more useful. Moreover, it would need to be
determined whether the SEMA3A pathway would be best targeted
at the level of the ligand or its receptor(s) and examined whether
anti-SEMA3A therapy would be well tolerated. Whether anti-
NRP1A antibodies that block SEMA3A-NRP1 interactions might also
be utilised to treat neovascular eye pathology has yet to be
assessed.
6.2.2. Therapeutic potential of targeting ECM signalling through
NRP1
NRP1 also promotes OIR-associated neovascularisation by
mediating ECM-driven ABL1 activation (Raimondi et al., 2014).
Should this pathway be found to contribute to human neovascular
disease, a potential therapeutic intervention may already be avail-
able in the form of Imatinib. Thus, it is conceivable that Imatinib
may be repurposed from its original use as an FDA-approved drug
for cancer treatment (www.fda.gov) as a drug to treat neovascular
eye disease. When administered systemically, as in cancer treat-
ment, Imatinib can cause bone marrow suppression due to its
potent inhibition of the hematopoietic stem cell regulator KIT
(Growney et al., 2005). However, intravitreal delivery of Imatinib in
ocular pathologies may circumvent this and other systemic side
effects. A ﬁrst step to assess the safety and efﬁcacy of intravitreal
Imatinib delivery for ocular neovascular disease might involve
follow-up of vascular normalisation in rodent models of OIR and
CNV combined with an investigation of neuroretinal health and
function after treatment.
6.3. Co-targeting of SEMA3A- and VEGF-signalling through NRP1
The intravitreal administration of a NRP1-derived ligand trap,
effective for both SEMA3A and VEGF164, reduced myeloid inﬁl-
tration and pathological neovascularisation in the OIR model
(Dejda et al., 2014). However, further work is required to determine
whether normalisation of endothelial cells, myeloid cells or both
explains the beneﬁcial effect of sequestering NRP1 ligands in
attenuating neovascularisation. Alternatively, soluble NRP1 might
be used to curb SEMA- and VEGF-dependent signalling in neo-
vascular diseases. Recent evidence showed that soluble NRP1 in-
hibits VEGF activity. Thus, genetically modiﬁed mice expressing a
soluble NRP1 form in the skin have a normal number of blood
vessels with only a mild reduction in the lumen size, but strongly
reduced vascular leakage after intradermal VEGF injection
(Mamluk et al., 2005). In agreement, soluble S12NRP1 has antitumor
activity when overexpressed in prostate cancer cells injected into
rats (Gagnon et al., 2000; Schuch et al., 2002). Moreover, quiescentmurine hepatocytes express high levels of soluble NRP1, which is
transiently downregulated after hepatectomy, and this correlates
with endothelial cell signalling to facilitate angiogenesis for liver
regeneration (Panigrahy et al., 2014). It has not yet been examined
whether the exogenous delivery of soluble form of NRP1might also
ameliorate neovascular eye diseases.
6.4. Micro RNA (miRNA)-mediated modulation of NRP1 expression
The discovery of miRNAs that regulate NRP1 expression (Bai
et al., 2015; Liu et al., 2015; Peng et al., 2014; Wu et al., 2014) is a
relatively new ﬁnding that may catalyse the development of novel
NRP1 therapeutics to target several different NRP1 functions in
parallel. miRNAs are small non-coding RNAs that regulate gene
expression by hybridising to sequences in mRNAs, most commonly
within in the 30 untranslated region, to degrade them or block their
translation (Dangwal and Thum, 2014). miRNA mimics are syn-
thetic RNA molecules that are designed according to template
miRNAs tomimic their function (reviewed in Bader et al., 2010). The
ﬁrst miRNA mimic, MRX34, has been brought to clinical trial with
the eventual aim of targeting liver cancer by mimicking miR-34a's
regulation of a plethora of oncogenes (Bouchie, 2013). The miRNAs
miR-338 and miR-320 are amongst the miRNAs that have been
shown to downregulate NRP1 expression, and their endothelial
expression is associated with reduced angiogenesis in vitro and in
tumour xenograft models (Peng et al., 2014; Wu et al., 2014).
Although it remains to be determined whether NRP1-targeting
miRNAs could be utilised to treat eye disease, the broad speci-
ﬁcity of miRNAs might be advantageous to downregulate gene
expression programmes that drive pathology. However, this same
property may also increase the risk of unexpected and unwanted
side effects.
7. Future directions
VEGF blockade is now ﬁrst line therapy for the treatment of
macular oedema in ischemic retinopathies. In the case of exudative
AMD, anti-VEGF therapy stabilises sight in over 90% of patients over
several years of treatment (Rosenfeld et al., 2011), whereby the
agent is administered by repeated monthly injection into the eye to
maintain the beneﬁcial effect (Schmidinger et al., 2011). Moreover,
30% of patients experience improved vision after anti-VEGF de-
livery (Rosenfeld et al., 2011). However, a signiﬁcant number of
patients do not beneﬁt from anti-VEGF, and a multi-cohort clinical
study examining the efﬁcacy of long-term anti-VEGF treatment
showed that only one third of patients had a good visual outcome at
seven years, whilst another third had a poor outcome (Rofagha
et al., 2013).
Inefﬁcacy of anti-VEGF therapy may result from the treatment's
inability to target established vascular lesions and/or prevent the
emergence of new lesions driven by VEGF-independent angio-
genesis pathways, such as ECM-induced angiogenesis. In addition,
several rodent studies suggest that blockade of all VEGF isoforms in
mouse models increases neuronal death in the mouse retina
(Nishijima et al., 2007; Park et al., 2014). As most anti-VEGF drugs
sequester all VEGF isoforms, neuroretinal degeneration due to a
loss of trophic VEGF effects may, at least in part, contribute to the
poor visual outcome observed with long-term treatment. Whilst
comparable long-term data are not available for anti-VEGF treat-
ment of DME, it is reasonable to suspect that similar pitfalls exist.
As long-term anti-VEGF monotherapy for exudative AMD has
limited efﬁcacy, does not work in all patients and has potential
neuronal side effects, there is a need for alternative treatments for
this and possibly other ischemic eye diseases. An alternative
strategy to treat neovascular disease may be to preferentially target
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serving VEGF120 signalling through VEGFR2 may be beneﬁcial,
especially for the long-term treatment of chronic diseases such as
exudative AMD. Here, wherein blockade of all VEGF isoformswould
likely increase neuronal death in the retina, preservation of
VEGF120 may be sufﬁcient to convey neuroprotection through
signalling to VEGFR2-expressing neurons (Foxton et al., 2013;
Nishijima et al., 2007; Saint-Geniez et al., 2008). In this respect,
targeting VEGF164 binding to NRP1 might have similar effects as
treatment with Macugen, an aptamer that speciﬁcally targets
VEGF164 and has been approved by the FDA for the treatment of
AMD, even though its clinical use has been superseded by anti-
VEGFs that target all isoforms (Ip et al., 2008; Rosenfeld, 2006).
As NRP1 regulates angiogenesis and permeability induced by
multiple signals, including VEGF, ECM and semaphorins, targeting
NRP1 pathways may offer numerous windows for intervention in
eye disease. Yet, it is the characteristics of the individual pathol-
ogies that should govern considerations on which type of NRP1-
based targeting approach might be explored. For example, a total
blockade of NRP1 signalling might be advisable when there is a
need to block VEGF-dependent, VEGF-independent and SEMA3-
dependent signalling through NRP1. Alternatively, it may be pref-
erable to exclusively target VEGF-dependent and SEMA3-
dependent NRP1 signalling, whilst leaving ECM/NRP1-driven
angiogenesis untouched to harness NRP1's positive roles in facili-
tating vascular tissue integration and thereby restoring blood ﬂow
to hypoxic tissues. More speciﬁcally, it may be desirable to promote
NRP1-mediated signalling to guide vessels along ECM remnants of
degenerated vasculature whilst blocking harmful NRP1 functions,
such as its ability to promote vascular hyperpermeability. With
NRP1 emerging as a promising therapeutic target for eye disease
and with encouraging therapeutic agents being developed, further
studies are clearly needed to deﬁne the speciﬁc mechanisms by
which NRP1 activates different disease-related pathways and to
hone in on pathology-speciﬁc applications.
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